Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Epistemonikos ID: 60a90fe772d0e98d373a5ddea4a54db663a5f67b
First added on: May 17, 2024